A Study of DPP-IV Inhibitor in Patients With Type 2 Diabetes
Public ClinicalTrials.gov record NCT00111670. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized, Double-blind Study of the Effect of the DPP-IV Inhibitor on HbA1c and Safety in Patients With Type 2 Diabetes
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This study will assess the efficacy, safety and tolerability of DPP-IV Inhibitor compared to placebo in patients with type 2 diabetes. The anticipated time on study treatment is \< 3 months and the target sample size is 100-500 individuals.
Study identification
- NCT ID
- NCT00111670
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 291 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years to 75 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- May 31, 2005
- Primary completion
- Jun 30, 2006
- Completion
- Jun 30, 2006
- Last update posted
- Nov 1, 2016
2005 – 2006
United States locations
- U.S. sites
- 18
- U.S. states
- 12
- U.S. cities
- 18
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Not listed | Salinas | California | 93901 | — |
| Not listed | Clearwater | Florida | 33765 | — |
| Not listed | Hialeah | Florida | 33013 | — |
| Not listed | Pembroke Pines | Florida | 33029 | — |
| Not listed | Blue Ridge | Georgia | 30513 | — |
| Not listed | Aurora | Illinois | 60504 | — |
| Not listed | Elkton | Maryland | 21921 | — |
| Not listed | Oxon Hill | Maryland | 20745 | — |
| Not listed | Troy | Michigan | 48098 | — |
| Not listed | Pahrump | Nevada | 89048 | — |
| Not listed | Cincinnati | Ohio | 45224 | — |
| Not listed | Portland | Oregon | 97239 | — |
| Not listed | Warminster | Pennsylvania | 18974 | — |
| Not listed | Dallas | Texas | 75246 | — |
| Not listed | Midland | Texas | 79707 | — |
| Not listed | San Antonio | Texas | 78229 | — |
| Not listed | Richmond | Virginia | 23249 | — |
| Not listed | Virginia Beach | Virginia | 23451 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 22 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00111670, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Nov 1, 2016 · Synced Sep 5, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00111670 live on ClinicalTrials.gov.